The company of eight released its first game in 2025, featuring a postman named Valentine with a heart-shaped head, who ...
Bacteria-scale robots that can run for months without human control are no longer a lab fantasy. Researchers have now built ...
Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and ...
A 13-year-old and his teen sister picked up vibe coding and ended up competing together in a 24-hour hackathon with their dad ...
Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...
RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
The Treasury Department announced Thursday an investigation into small-business government contracts worth about $9 billion and whether federal programs have been used fraudulently. The department is ...